Use of naltrexone as a provocative test for hypothalamic-pituitary hormone function.
Naltrexone (50 mg) administration to normal adult women during the early follicular phase of the menstrual cycle (day 1 to day 4 following onset of menstruation) induced a significant elevation in plasma LH, prolactin, ACTH and cortisol levels. Orally administered naltrexone appears to be a safe and effective compound for assessing function of the hypothalamic-anterior pituitary axis in women.
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007031:Hypothalamus / Q000502:physiology*; D007273:Injections, Intramuscular; D007986:Luteinizing Hormone / Q000097:blood; D009271:Naltrexone; D010901:Pituitary Function Tests; D010903:Pituitary Gland, Anterior / Q000502:physiology*; D011388:Prolactin / Q000097:blood; D013997:Time Factors
D009271:Naltrexone; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D006854:Hydrocortisone